DXLAB INC

SOMERVILLE, MA · Founded 2020 · CIK 0001834512 · Medtech · Private

Platform for rapid, point-of-care molecular testing

dxlab.bio →
Grants
$74K
1 award
Sector median: 1
Raised
$4.0M
1 Form D · Dec 2020
69 months since last filing
Contracts
$1.2M
1 award · Defense
#285 of 4531 in medtech
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,999,986
Federal grantDepartment of Defense · Phase I · FDA-authorized, point-of care diagnostic platform for rapid and sensitive detection of harmful pathogens.$74,399
Federal contractDepartment of Defense · SBIR Phase II Proposal F2-17053 - Portable And Rugged Infection Diagnostic Platform Providing Rapid, Clinically Actionable Pathogen Detection At Deployed Locations And Military Treatment Facilities$1,249,994
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
282MEDSHAPE, INC.$1.3M$3.1M
283ENUMAGE INC.$1.3M—
284INTELLIGENT HEARING SYSTEMS$1.3M—
285DXLAB INC$1.2M$4.0M
286XSONX, LLC$1.2M—
287Siloam Vision, Inc.$1.2M$3.2M
288COURTESY CUPS, LLC$1.2M—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Calvin ChinDirector
  • Fahim FarzadfardDirector
  • Jeong Seuk KangDirector
  • Adam MullinaxDirector
  • Ho-Jun SukDirector · Executive Officer

Patents

USPTO · 0 granted of 2
  • Methods For Detection Of Nucleic Acidsapplication
  • Methods For Detection Of Nucleic Acidsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.